- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Moderate to severe menopause-related vasomotor symptoms
- Meeting Date: March 2025
- Public Summary Document (PSD) March 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2025 PBAC Meeting - (Word)
Fezolinetant – March 2025
Fezolinetant; Tablet 45 mg; Veoza®
Last updated
12 March 2025